Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Overview of Findings: Apremilast Enhances Dermatological Outcomes in Children with Shorter-Duration Plaque Psoriasis: 52-Week Data from the SPROUT Phase 3 Study

  • By

  • Richard G. Langley

  • Lisa Arkin

  • Loretta Fiorillo

  • Lawrence F. Eichenfield

  • Mark Lebwohl

  • Bruce Strober

  • Michael Sticherling

  • Lisa Swanson

  • Georgios Kokolakis

  • Siddharth Chaudhari

  • Cynthia Deignan

  • Zuoshun Zhang

  • Amy S. Paller

  • May 14, 2026

Share

Objective:

To evaluate the efficacy of Apremilast in improving dermatological outcomes in pediatric patients with shorter-duration plaque psoriasis over a 52-week period.

Key Findings:
  • Apremilast significantly improved skin outcomes in children with shorter-duration plaque psoriasis.
  • The treatment was well-tolerated over the 52-week study period.
Interpretation:

The findings suggest that Apremilast is an effective treatment option for pediatric patients with shorter-duration plaque psoriasis, potentially leading to better management of the condition.

Limitations:
  • The study focused only on children with shorter-duration psoriasis, limiting generalizability to all pediatric psoriasis patients.
  • Long-term effects beyond 52 weeks were not assessed.
Conclusion:

Apremilast shows promise in enhancing dermatological outcomes in children with shorter-duration plaque psoriasis, warranting further research.

Original Source(s)

Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial

  • by Richard G. Langley, Lisa Arkin, Loretta Fiorillo, Lawrence F. Eichenfield, Mark Lebwohl, Bruce Strober, Michael Sticherling, Lisa Swanson, Georgios Kokolakis, Siddharth Chaudhari, Cynthia Deignan, Zuoshun Zhang, Amy S. Paller

  • May 14, 2026

Related Content

Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b

Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.

Psychological impact and quality of life in pediatric patients with chronic skin disorders: a systematic review (2010–2025)